TY - JOUR
T1 - The dolabellane diterpenes as potential inhibitors of the SARS-CoV-2 main protease
T2 - molecular insight of the inhibitory mechanism through computational studies
AU - Aminah, Nanik Siti
AU - Abdjan, Muhammad Ikhlas
AU - Wardana, Andika Pramudya
AU - Kristanti, Alfinda Novi
AU - Siswanto, Imam
AU - Rakhman, Khusna Arif
AU - Takaya, Yoshiaki
N1 - Publisher Copyright:
© The Royal Society of Chemistry 2021.
PY - 2021/12/10
Y1 - 2021/12/10
N2 - An investigation has been carried out on natural products from dolabellane derivatives to understand their potential in inhibiting the SARS-CoV-2 main protease (3CLpro) using anin silicoapproach. Inhibition of the 3CLproenzyme is a promising target in stopping the replication of the SARS-CoV-2 virus through inhibition of the subsite binding pocket. The redocking process aims to determine the 3CLproactive sites. The redocking requirement showed a good pose with an RMSD value of 1.39 Å. The combination of molecular docking and MD simulation shows the results of DD13 as a candidate which had a good binding affinity (kcal mol−1) to inhibit the 3CLproenzyme activity. Prediction of binding free energy (kcal mol−1) of DD13 using the Molecular Mechanics-Poisson Boltzmann/Generalized Born Surface Area (MM-PB/GBSA) approach shows the results ΔGbind(MM-GBSA): −52.33 ± 0.34 and ΔGbind(MM-PBSA): −43.52 ± 0.42. The key residues responsible for the inhibition mechanism are Hie41, Ser46, Met49, Asn142, Cys145, Hie163, Met165, and Gln189. Additionally, pharmacokinetic prediction recommended that DD13 had promising criteria as a drug candidate. The results demonstrated in this study provide theoretical information to obtain a potential inhibitor against the SARS-CoV-2 main protease.
AB - An investigation has been carried out on natural products from dolabellane derivatives to understand their potential in inhibiting the SARS-CoV-2 main protease (3CLpro) using anin silicoapproach. Inhibition of the 3CLproenzyme is a promising target in stopping the replication of the SARS-CoV-2 virus through inhibition of the subsite binding pocket. The redocking process aims to determine the 3CLproactive sites. The redocking requirement showed a good pose with an RMSD value of 1.39 Å. The combination of molecular docking and MD simulation shows the results of DD13 as a candidate which had a good binding affinity (kcal mol−1) to inhibit the 3CLproenzyme activity. Prediction of binding free energy (kcal mol−1) of DD13 using the Molecular Mechanics-Poisson Boltzmann/Generalized Born Surface Area (MM-PB/GBSA) approach shows the results ΔGbind(MM-GBSA): −52.33 ± 0.34 and ΔGbind(MM-PBSA): −43.52 ± 0.42. The key residues responsible for the inhibition mechanism are Hie41, Ser46, Met49, Asn142, Cys145, Hie163, Met165, and Gln189. Additionally, pharmacokinetic prediction recommended that DD13 had promising criteria as a drug candidate. The results demonstrated in this study provide theoretical information to obtain a potential inhibitor against the SARS-CoV-2 main protease.
UR - http://www.scopus.com/inward/record.url?scp=85121543635&partnerID=8YFLogxK
U2 - 10.1039/d1ra07584e
DO - 10.1039/d1ra07584e
M3 - Article
AN - SCOPUS:85121543635
SN - 2046-2069
VL - 11
SP - 39455
EP - 39466
JO - RSC Advances
JF - RSC Advances
IS - 62
ER -